Companies › BrainChild Bio
1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Oct 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| BCB-276 B7-H3-targeted autologous CAR T cell therapy | – | Phase 2 | Diffuse Intrinsic Pontine Glioma | Oct 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07680439 | BCB-276 | Phase 2 | Diffuse Intrinsic Pontine Glioma | Oncology | Oct 2028 |
No annotated target.
–
Newish Technology (Beijing) TVAX Biomedical Lukas Biomedical RhoVac APS March Biosciences
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.